10 February 2026
10 February 2026
The total number of patients enrolled across both parts is anticipated to exceed 650.
Veradermics completed enrolment for both Phase III VDPHL01 trials in male pattern hair loss, totalling over 1,000 participants.
The partnership aims to advance high-priority small molecule programmes using Iambic’s AI models and wet lab capabilities.
VERITAS involved 400 patients at 34 sites across Europe, Canada, and the US.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
